推荐产品
等级
pharmaceutical primary standard
API类
donepezil
制造商/商品名称
USP
应用
pharmaceutical (small molecule)
包装形式
neat
SMILES字符串
Cl.N2(CCC(CC2)CC3Cc4c(cc(c(c4)OC)OC)C3=O)Cc1ccccc1
InChI
1S/C24H29NO3.ClH/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18;/h3-7,14-15,17,20H,8-13,16H2,1-2H3;1H
InChI key
XWAIAVWHZJNZQQ-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
分析说明
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他说明
Sales restrictions may apply.
相关产品
产品编号
说明
价格
警示用语：
Danger
危险声明
危险分类
Acute Tox. 2 Oral - Eye Irrit. 2
储存分类代码
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
其他客户在看
Warren B Zigman
Developmental disabilities research reviews, 18(1), 51-67 (2013-08-21)
At present, there may be over 210,000 people with Down syndrome (DS) over the age of 55 in the United States (US) who have significant needs for augmented services due to circumstances related to ordinary and/or pathological aging. From 1979
F M Garlich et al.
Clinical toxicology (Philadelphia, Pa.), 52(4), 291-294 (2014-04-17)
Donepezil is a centrally-acting, reversible acetylcholinesterase inhibitor that is used in the treatment of Alzheimer disease. Altered mental status, nausea, vomiting, and bradycardia have been reported in therapeutic and supratherapeutic ingestions of donepezil, though pediatric exposures have not been well-described.
H Sugimoto et al.
Current medicinal chemistry, 7(3), 303-339 (2000-01-19)
A wide range of evidence shows that acetylcholinesterase (AChE) inhibitors can interfere with the progression of Alzheimer's disease (AD). The successful development of these compounds was based on a well-accepted theory that the decline in cognitive and mental functions associated
Koteswara Rao Valasani et al.
Journal of chemical information and modeling, 53(8), 2033-2046 (2013-06-20)
Acetylcholinesterase (AChE) is a main drug target, and its inhibitors have demonstrated functionality in the symptomatic treatment of Alzheimer's disease (AD). In this study, a series of novel AChE inhibitors were designed and their inhibitory activity was evaluated with 2D
Manabu Ikeda et al.
Dementia and geriatric cognitive disorders, 36(3-4), 229-241 (2013-08-21)
To investigate the safety and efficacy of long-term administration (52 weeks) of donepezil in patients with dementia with Lewy bodies (DLB). This was a 52-week, multicenter, open-label extension study. Up to 8 weeks after the completion of the preceding randomized
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持